Clinical trials recruiting for Esophageal cancer
65
Recruiting trials
36
US states with sites
22
Countries
15%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Pembrolizumab | 4 |
| BL-B01D1 | 2 |
| Bevacizumab | 2 |
| CEA-targeted CAR-T cells | 2 |
| Carboplatin | 2 |
| Nivolumab | 2 |
| 64Cu-LNTH-1363S | 1 |
| AB122 | 1 |
| AB154 | 1 |
| APG-2449 | 1 |
| BL-M07D1 | 1 |
| BL-M17D1 | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Texas | 21 |
| Florida | 17 |
| California | 16 |
| Tennessee | 14 |
| Massachusetts | 13 |
| Colorado | 11 |
| Ohio | 11 |
| New York | 10 |
| Missouri | 9 |
| Pennsylvania | 8 |
| Illinois | 7 |
| Michigan | 7 |
Top cities
Houston, Texas 16Nashville, Tennessee 14Boston, Massachusetts 12New York, New York 9Duarte, California 7Los Angeles, California 6San Antonio, Texas 6San Diego, California 6St Louis, Missouri 6Miami, Florida 5
Self-screener
Recruiting trials
- 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
- A Beta-only IL-2 ImmunoTherapY Study
- A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)
- A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- A Study of SH009 Injection in Patients With Advanced Solid Tumors.
- A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
- A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
- A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- AB122 Platform Study
- AI-Assisted Non-Contrast CT for Multi-Cancer Screening
- APG-2449 in Patients With Advanced Solid Tumors
- Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
- Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- Brodalumab in the Treatment of Immune-Related Adverse Events
- CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
- CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors
- COMBO Endoscopy Oropharyngeal Airway Reduces Hypoxia During Sedated Gastrointestinal Endoscopy in Obese Patients: A Multicenter, Randomized, Controlled Clinical Trial
- Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
- Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors
- Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients
- DESTINY-PANTUMOUR04
- Distance-Based Exercise to Preserve Function and Prevent Disability
- Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
- EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
- Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac
- Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
- IDOV-Immune for Advanced Solid Tumors
- Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients
- Integrated Cancer Repository for Cancer Research
- Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients
- Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
- Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Pan-tumor MRD Study
- Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
- Phase 1 Study of PF-08046033 in Advanced Solid Tumors
- Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
- Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
- Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery
- Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
- Resilience and Equity in Aging, Cancer, and Health (REACH)
- SL-28 for Advanced Solid Tumours
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Serial MRI Scans During Radiation Therapy
- Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
- TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
- The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.
- The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
- The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III
- Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
- Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
- Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
- VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- a Single-arm, Single-center, Open Clinical Study
- cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Related conditions
Trials recruiting for Esophageal cancer often also study these conditions. Each links to its own recruiting-trial list.
Lung cancer 2180Pancreatic cancer 870Colorectal cancer 1359Gastric cancer 91Breast cancer 2239Prostate cancer 1234Head and neck cancer 62Ovarian cancer 118Cervical cancer 71Bladder cancer 59
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Esophageal cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.